Cited by 273Inflammasome and immune disordersAcute Myeloid Leukemia ResearchBlood disorders and treatments

The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.

The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes

Open access

Sallman, David A., List, Alan·2019·Blood

DOI 10.1182/blood-2018-10-844654PMC PMC7022316

Open this paper in CoChat — free account Open PDF

Abstract

In cancer biology, tumor-promoting inflammation and an inflammatory microenvironment play a vital role in disease pathogenesis. In the past decade, aberrant innate immune activation and proinflammatory signaling within the malignant clone and the bone marrow (BM) microenvironment were identified as key pathogenic drivers of myelodysplastic syndromes (MDS). In particular, S100A9-mediated NOD-like receptor protein 3 (NLRP3) inflammasome activation directs an inflammatory, lytic form of cell death termed pyroptosis that underlies many of the hallmark features of the disease. This circuit and accompanying release of other danger-associated molecular patterns expands BM myeloid-derived suppressor cells, creating a feed-forward process propagating inflammasome activation. Furthermore, somatic gene mutations of varied functional classes license the NLRP3 inflammasome to generate a common phenotype with excess reactive oxygen species generation, Wnt/β-catenin-induced proliferation, cation flux-induced cell swelling, and caspase-1 activation. Recent investigations have shown that activation of the NLRP3 inflammasome complex has more broad-reaching importance, particularly as a possible disease-specific biomarker for MDS, and, mechanistically, as a driver of cardiovascular morbidity/mortality in individuals with age-related, clonal hematopoiesis. Recognition of the mechanistic role of aberrant innate immune activation in MDS provides a new perspective for therapeutic development that could usher in a novel class of disease-modifying agents.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1182/blood-2018-10-844654

Cites

81 of 81 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses
Taganov, K. D., Boldin, M. P., Chang, K.-J., & Baltimore, D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605298103 · Cited by 4,317
Toll-like receptor control of the adaptive immune responses
Iwasaki, A., & Medzhitov, R. M. (2004) · Nature Immunology · doi:10.1038/ni1112 · Cited by 4,166
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Pyroptosis: host cell death and inflammation
Bergsbaken, T., Fink, S. L., & Cookson, B. T. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2070 · Cited by 3,288
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G. F., Garcia‐Manero, G., Solé, F. G., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., et al. (2012) · Blood · doi:10.1182/blood-2012-03-420489 · Cited by 3,224
Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores
Liu, X., Zhang, Z., Ruan, J., Pan, Y., Magupalli, V. G., Wu, H., & Lieberman, J. (2016) · Nature · doi:10.1038/nature18629 · Cited by 3,202
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Coll, R. C., Robertson, A. A. B., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3806 · Cited by 2,849
Pore-forming activity and structural autoinhibition of the gasdermin family
Ding, J., Wang, K., Liu, W., She, Y., Sun, Q., Shi, J., Sun, H., Wang, D.-C., & Shao, F. (2016) · Nature · doi:10.1038/nature18590 · Cited by 2,771
Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease
Jaiswal, S., Natarajan, P., Silver, A. J., Gibson, C. J., Bick, A. G., Shvartz, E., McConkey, M., Gupta, N., Gabriel, S., Ardissino, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701719 · Cited by 2,683
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663
Targeting the NLRP3 inflammasome in inflammatory diseases
Mangan, M. S. J., Olhava, E. J., Roush, W. R., Seidel, H. M., Glick, G. D., & Latz, E. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.97 · Cited by 1,885
Age-related mutations associated with clonal hematopoietic expansion and malignancies
Xie, M., Lu, C., Wang, J., McLellan, M. D., Johnson, K. J., Wendl, M. C., McMichael, J. F., Schmidt, H. K., Yellapantula, V., Miller, C. A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3733 · Cited by 1,874
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,812
Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice
Fuster, J. J., MacLauchlan, S., Zuriaga, M. A., Polackal, M. N., Ostriker, A. C., Chakraborty, R., Wu, C.-L., Sano, S., Muralidharan, S., Rius, C., et al. (2017) · Science · doi:10.1126/science.aag1381 · Cited by 1,536
Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock
Vogl, T., Tenbrock, K., Ludwig, S., Leukert, N., Ehrhardt, C., van Zoelen, M. A. D., Nacken, W., Foell, D., van der Poll, T., Sorg, C., et al. (2007) · Nature Medicine · doi:10.1038/nm1638 · Cited by 1,418
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
Ridker, P. M., MacFadyen, J. G., Thuren, T., Everett, B. M., Libby, P., Glynn, R. J., Ridker, P., Lorenzatti, A., Krum, H., Varigos, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32247-x · Cited by 1,344
Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion
List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061292 · Cited by 1,319
Self-citation
NF-κB Restricts Inflammasome Activation via Elimination of Damaged Mitochondria
Zhong, Z., Umemura, A., Sanchez-Lopez, E., Liang, S., Shalapour, S., Wong, J., He, F., Boassa, D., Perkins, G., Ali, S. R., et al. (2016) · Cell · doi:10.1016/j.cell.2015.12.057 · Cited by 1,197
GSDMD membrane pore formation constitutes the mechanism of pyroptotic cell death
Sborgi, L., Rühl, S., Mulvihill, E., Pipercevic, J., Heilig, R., Stahlberg, H., Farady, C. J., Müller, D. J., Broz, P., & Hiller, S. (2016) · The EMBO Journal · doi:10.15252/embj.201694696 · Cited by 1,152
Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia
Raaijmakers, M. H. G. P., Mukherjee, S., Guo, S., Zhang, S., Kobayashi, T., Schoonmaker, J. A., Ebert, B. L., Al-Shahrour, F., Hasserjian, R. P., Scadden, E. O., et al. (2010) · Nature · doi:10.1038/nature08851 · Cited by 1,115
IL-1 is required for tumor invasiveness and angiogenesis
Voronov, E., Shouval, D. S., Krelin, Y., Cagnano, E., Benharroch, D., Iwakura, Y., Dinarello, C. A., & Apte, R. N. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437939100 · Cited by 1,033
Type I Interferon Inhibits Interleukin-1 Production and Inflammasome Activation
Guarda, G., Braun, M., Staehli, F., Tardivel, A., Mattmann, C., Förster, I., Farlik, M., Decker, T., Pasquier, R. D., Romero, P. J., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.02.006 · Cited by 924
GsdmD p30 elicited by caspase-11 during pyroptosis forms pores in membranes
Aglietti, R. A., Estevez, A., Gupta, A., Ramirez, M. G., Liu, P. S., Kayagaki, N., Ciferri, C., Dixit, V. M., & Dueber, E. C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607769113 · Cited by 898
The endogenous Toll–like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer
Ehrchen, J. M., Sunderkötter, C. H., Foell, D., Vogl, T., & Roth, J. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.1008647 · Cited by 869
Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6
Zhang, Q., Zhao, K., Shen, Q., Han, Y., Gu, Y., Li, X., Zhao, D., Liu, Y., Wang, C., Zhang, X., et al. (2015) · Nature · doi:10.1038/nature15252 · Cited by 807
Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly
Zink, F., Stacey, S. N., Norddahl, G. L., Frigge, M. L., Magnusson, O. T., Jonsdottir, I., Thorgeirsson, T. E., Sigurdsson, A., Gudjonsson, S. A., Gudmundsson, J., et al. (2017) · Blood · doi:10.1182/blood-2017-02-769869 · Cited by 777
The adaptor ASC has extracellular and 'prionoid' activities that propagate inflammation
Franklin, B. S., Bossaller, L., De Nardo, D., Ratter, J. M., Stutz, A., Engels, G., Brenker, C., Nordhoff, M., Mirandola, S. R., Al-Amoudi, A., et al. (2014) · Nature Immunology · doi:10.1038/ni.2913 · Cited by 773
Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells
Sinha, P., Okoro, C., Foell, D., Freeze, H. H., Ostrand‐Rosenberg, S., & Srikrishna, G. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.4666 · Cited by 737
Reduced Inflammation in the Tumor Microenvironment Delays the Accumulation of Myeloid-Derived Suppressor Cells and Limits Tumor Progression
Bunt, S. K., Yang, L., Sinha, P., Clements, V. K., Leips, J., & Ostrand‐Rosenberg, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2354 · Cited by 630
Somatic mutations precede acute myeloid leukemia years before diagnosis
Desai, P., Mencia-Trinchant, N., Savenkov, O., Simon, M. S., Cheang, G., Lee, S., Samuel, M., Ritchie, E. K., Guzman, M. L., Ballman, K. V., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0081-z · Cited by 619
Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotype
Starczynowski, D. T., Kuchenbauer, F., Argiropoulos, B., Sung, S., Morin, R., Muranyi, A., Hirst, M., Hogge, D., Marra, M., Wells, R. A., et al. (2010) · Nature Medicine · doi:10.1038/nm.2054 · Cited by 577
Inflammation Induces Myeloid-Derived Suppressor Cells that Facilitate Tumor Progression
Bunt, S. K., Sinha, P., Clements, V. K., Leips, J., & Ostrand‐Rosenberg, S. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.284 · Cited by 537
Erratum: Targeting the NLRP3 inflammasome in inflammatory diseases
Mangan, M. S. J., Olhava, E. J., Roush, W. R., Seidel, H. M., Glick, G. D., & Latz, E. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.149 · Cited by 465
Bruton’s tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury
Ito, M., Shichita, T., Okada, M., Komine, R., Noguchi, Y., Yoshimura, A., & Morita, R. (2015) · Nature Communications · doi:10.1038/ncomms8360 · Cited by 417
Pyroptosis triggers pore-induced intracellular traps (PITs) that capture bacteria and lead to their clearance by efferocytosis
Jorgensen, I., Zhang, Y., Krantz, B. A., & Miao, E. A. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151613 · Cited by 403
ASC filament formation serves as a signal amplification mechanism for inflammasomes
Dick, M. S., Sborgi, L., Rühl, S., Hiller, S., & Broz, P. (2016) · Nature Communications · doi:10.1038/ncomms11929 · Cited by 394
The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype
Basiorka, A. A., McGraw, K. L., Eksioglu, E. A., Chen, X., Johnson, J., Zhang, L., Zhang, Q., Irvine, B. A., Cluzeau, T., Sallman, D. A., et al. (2016) · Blood · doi:10.1182/blood-2016-07-730556 · Cited by 367
Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins
Lee, S. C.-W., Dvinge, H., Kim, E. H., Cho, H., Micol, J., Chung, Y. R., Durham, B. H., Yoshimi, A., Kim, Y. J., Thomas, M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4097 · Cited by 359
Mesenchymal inflammation drives genotoxic stress in hematopoietic stem cells and predicts disease evolution in human pre-leukemia
Zambetti, N. A., Ping, Z., Chen, S., Kenswil, K. J. G., Mylona, M. A., Sanders, M. A., Hoogenboezem, R. M., Bindels, E. M. J., Adisty, M. N., Van Strien, P. M. H., et al. (2016) · Cell stem cell · doi:10.1016/j.stem.2016.08.021 · Cited by 342
Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo
Abdel-Wahab, O. I., Gao, J., Adli, M., Dey, A., Trimarchi, T., Chung, Y. R., Kuscu, C., Hricik, T., Ndiaye‐Lobry, D., LaFave, L. M., et al. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20131141 · Cited by 335
Induction of myelodysplasia by myeloid-derived suppressor cells
Chen, X., Eksioglu, E. A., Zhou, J., Zhang, L., Djeu, J., Fortenbery, N., Epling-Burnette, P., Van Bijnen, S., Dolstra, H., Cannon, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67580 · Cited by 316
Self-citation
MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice
Perera, A. P., Fernando, R., Shinde, T., Gundamaraju, R., Southam, B., Sohal, S. S., Robertson, A. A. B., Schroder, K., Kunde, D., & Eri, R. D. (2018) · Scientific Reports · doi:10.1038/s41598-018-26775-w · Cited by 306
The Augmented R-Loop Is a Unifying Mechanism for Myelodysplastic Syndromes Induced by High-Risk Splicing Factor Mutations
Chen, L., Chen, J., Huang, Y.-J., Gu, Y., Qiu, J., Qian, H., Shao, C., Zhang, X., Hu, J., Li, H., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2017.12.029 · Cited by 304
Chronic Immune Stimulation Might Act As a Trigger for the Development of Acute Myeloid Leukemia or Myelodysplastic Syndromes
Kristinsson, S. Y., Björkholm, M., Hultcrantz, M. L., Derolf, Å. R., Landgren, O., & Goldin, L. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.8540 · Cited by 289
S100A8 and S100A9 Induce Cytokine Expression and Regulate the NLRP3 Inflammasome via ROS-Dependent Activation of NF-κB1
Simard, J.-C., Césaro, A., Chapeton-Montes, J. A., Tardif, M. R., Antoine, F., Girard, D., & Tessier, P. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072138 · Cited by 274
Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9
Schneider, R. K., Schenone, M., Ferreira, M. S. V., Kramann, R., Joyce, C. E., Hartigan, C. R., Beier, F., Brümmendorf, T. H., Germing, U., Platzbecker, U., et al. (2016) · Nature Medicine · doi:10.1038/nm.4047 · Cited by 246
Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes
Gañán-Gómez, I., Wei, Y., Starczynowski, D. T., Colla, S., Yang, H., Cabrero-Calvo, M., Bohannan, Z. S., Verma, A., Steidl, U., & Garcia-Manero, G. (2015) · Leukemia · doi:10.1038/leu.2015.69 · Cited by 236
Chronic immune response dysregulation in MDS pathogenesis
Barreyro, L., Chlon, T. M., & Starczynowski, D. T. (2018) · Blood · doi:10.1182/blood-2018-03-784116 · Cited by 226
Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations
Lee, S. C.-W., North, K., Kim, E., Jang, E., Obeng, E., Lu, S. X., Liu, B., Inoue, D., Yoshimi, A., Ki, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.003 · Cited by 219
Methyltransferase Dnmt3a upregulates HDAC9 to deacetylate the kinase TBK1 for activation of antiviral innate immunity
Li, X., Zhang, Q., Ding, Y., Liu, Y., Zhao, D., Zhao, K., Shen, Q., Liu, X., Zhu, X., Li, N., et al. (2016) · Nature Immunology · doi:10.1038/ni.3464 · Cited by 206
Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome
Rhyasen, G. W., Bolanos, L., Fang, J., Jerez, A., Wunderlich, M., Rigolino, C., Mathews, L., Ferrer, M., Southall, N., Guha, R., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.006 · Cited by 199
Alarmin S100A8/S100A9 as a biomarker for molecular imaging of local inflammatory activity
Vogl, T., Eisenblätter, M., Völler, T., Zenker, S., Hermann, S., van Lent, P., Faust, A., Geyer, C., Petersen, B., Roebrock, K., et al. (2014) · Nature Communications · doi:10.1038/ncomms5593 · Cited by 197
The structure of rotational bands in alpha-cluster nuclei
Bijker, R. (2015) · EPJ Web of Conferences · doi:10.1051/epjconf/20159301011 · Cited by 184
Toll-like receptor alterations in myelodysplastic syndrome
Wei, Y., Dimicoli, S., Bueso‐Ramos, C. E., Chen, R., Yang, H., Neuberg, D. S., Pierce, S. A., Jia, Y., Zheng, H., Wang, H., et al. (2013) · Leukemia · doi:10.1038/leu.2013.180 · Cited by 159
Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines.
Raza (1996) · International Journal of Hematology · doi:10.1016/0925-5710(96)00455-0 · Cited by 141
Toll-like Receptor-4 Is Up-Regulated in Hematopoietic Progenitor Cells and Contributes to Increased Apoptosis in Myelodysplastic Syndromes
Maratheftis, C. I., Andreakos, E., Moutsopoulos, H. Μ., & Voulgarelis, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2108 · Cited by 140
Human NACHT, LRR, and PYD domain–containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase
Liu, X., Pichulik, T., Wolz, O., Dang, T., Stutz, A., Dillen, C. A., Garcia, M. D., Kraus, H., Dickhöfer, S., Daiber, E., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.01.017 · Cited by 137
U2AF35(S34F) Promotes Transformation by Directing Aberrant ATG7 Pre-mRNA 3′ End Formation
Park, S. M., Ou, J., Chamberlain, L., Simone, T. M., Yang, H., Virbasius, C.-M. A., Ali, A. M., Zhu, L. J., Mukherjee, S., Raza, A., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.04.011 · Cited by 135
Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype
Sallman, D. A., Cluzeau, T., Basiorka, A. A., & List, A. F. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00151 · Cited by 117
Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor–TRAF6 signaling
Varney, M. E., Niederkorn, M., Konno, H., Matsumura, T., Gohda, J., Yoshida, N., Akiyama, T., Christie, S., Fang, J., Miller, D., et al. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20141898 · Cited by 111
Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1
Fang, J., Rhyasen, G. W., Bolanos, L. C., Rasch, C., Varney, M. E., Wunderlich, M., Goyama, S., Jansen, G., Cloos, J. J., Rigolino, C., et al. (2012) · Blood · doi:10.1182/blood-2012-02-407999 · Cited by 109
Hyperactive mTOR pathway promotes lymphoproliferation and abnormal differentiation in autoimmune lymphoproliferative syndrome
Völkl, S., Rensing‐Ehl, A., Allgäuer, A., Schreiner, E., Lorenz, M. R., Rohr, J., Klemann, C., Fuchs, I., Schuster, V. H., von Bueren, A. O., et al. (2016) · Blood · doi:10.1182/blood-2015-11-685024 · Cited by 100
Reduction in C‐reactive protein indicates successful targeting of the IL‐1/IL‐6 axis resulting in improved survival in early stage multiple myeloma
Lust, J. A., Lacy, M. Q., Zeldenrust, S. R., Witzig, T. E., Moon‐Tasson, L. L., Dinarello, C. A., & Donovan, K. A. (2016) · American Journal of Hematology · doi:10.1002/ajh.24352 · Cited by 95
Interleukin‐1 in multiple myeloma: producer cells and their role in the control of IL‐6 production
Costes, V., Portier, M., Lu, Z., Rossi, J., Bataille, R., & Klein, B. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.01101.x · Cited by 88
Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells
Wei, Y., Chen, R., Dimicoli, S., Bueso‐Ramos, C. E., Neuberg, D. S., Pierce, S. A., Wang, H., Yang, H., Jia, Y., Zheng, H., et al. (2013) · Leukemia · doi:10.1038/leu.2013.91 · Cited by 84
S-adenosylhomocysteine induces inflammation through NFkB: A possible role for EZH2 in endothelial cell activation
Barroso, M., Kao, D. D., Blom, H. J., de Almeida, I. T., Castro, R., Loscalzo, J., & Handy, D. E. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.10.019 · Cited by 82
Age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis mimicking del(5q) MDS
Mei, Y., Zhao, B., Basiorka, A. A., Yang, J. C., Cao, L., Zhang, J., List, A. F., & Ji, P. (2017) · Leukemia · doi:10.1038/leu.2017.326 · Cited by 72
Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858
Eksioglu, E. A., Chen, X., Heider, K.-H., Rueter, B., McGraw, K. L., Basiorka, A. A., Wei, M., Burnette, A., Cheng, P., Lancet, J., et al. (2017) · Leukemia · doi:10.1038/leu.2017.21 · Cited by 66
Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study
Basiorka, A. A., McGraw, K. L., Aghababazadeh, F. A., McLemore, A. F., Vincelette, N. D., Ward, G., Eksioglu, E. A., Sallman, D. A., Ali, N. E. A., Padron, E., et al. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30109-1 · Cited by 60
Circulating S100A8 and S100A9 protein levels in plasma of patients with acquired aplastic anemia and myelodysplastic syndromes
Giudice, V., Wu, Z., Kajigaya, S., Ibanez, M. D. P. F., Rios, O. J., Cheung, F., Ito, S., & Young, N. S. (2018) · Cytokine · doi:10.1016/j.cyto.2018.06.025 · Cited by 51
Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes
Cluzeau, T., McGraw, K. L., Irvine, B. A., Masala, E., Adès, L., Basiorka, A. A., Maciejewski, J. P., Auberger, P., Wei, S., Fenaux, P., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.158857 · Cited by 49
KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice
Wei, Y., Zheng, H., Bao, N., Jiang, S., Bueso-Ramos, C., Khoury, J. D., Class, C. A., Lu, Y., Lin, K., Yang, H., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018024166 · Cited by 44
TET1 is a negative transcriptional regulator of IL-1β in the THP-1 cell line
Neves‐Costa, A., & Moita, L. F. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2012.12.014 · Cited by 38
Apoptosis in human myelodysplastic syndrome CD34+ cells is modulated by the upregulation of TLRs and histone H4 acetylation via a β-arrestin 1 dependent mechanism
Zeng, Q., Shu, J. S., Hu, Q., Shao-hong, Z., Qian, Y., Hu, M., Hu, L., Wang, Y., Zhou, Y., & Lü, J. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.12.008 · Cited by 29
An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes
Daher, M., Lopez, J. E. H., Randhawa, J. K., Jabbar, K. J., Wei, Y., Pemmaraju, N., Borthakur, G. M., Kadia, T. M., Konopleva, M. Y., Kantarjian, H. M., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24746 · Cited by 26
A Clinical Study of OPN-305, a Toll-like Receptor 2 (TLR-2) Antibody, in Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received Prior Hypomethylating Agent (HMA) Therapy
Garcia‐Manero, G., Bravo, G. M., Yang, H., Wei, Y., Alvarado, Y., Dinardo, C. D., Daver, N. G., Konopleva, M. Y., Hearn, K. P., Miller, R. M., et al. (2016) · Blood · doi:10.1182/blood.v128.22.227.227 · Cited by 23
SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes
Sallman, D. A., Tanaka, T. N., List, A. F., & Bejar, R. L. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.09.018 · Cited by 12

Sorted by citations

Inflammation as a regulator of hematopoietic stem cell function in disease, aging, and clonal selection
Caiado, F., Pietras, E. M., & Manz, M. G. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201541 · Cited by 289
Inflammation-Induced Tumorigenesis and Metastasis
Hibino, S., Kawazoe, T., Kasahara, H., Itoh, S., Ishimoto, T., Sakata‐Yanagimoto, M., & Taniguchi, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115421 · Cited by 319
Hallmarks of ribosomopathies
Kampen, K. R., Sulima, S. O., Vereecke, S., & Keersmaecker, K. D. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz637 · Cited by 231
Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS
Trowbridge, J. J., & Starczynowski, D. T. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201544 · Cited by 189
Pharmacological Inhibition of the Nod-Like Receptor Family Pyrin Domain Containing 3 Inflammasome with MCC950
Corcoran, S. E., Halai, R., & Cooper, M. A. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000171 · Cited by 180

See all 273

Authors: Sallman, D. A., & List, A.
Affiliations: Moffitt Cancer Center (US)
ORCID: Sallman, David A.
List, Alan
Venue: Blood
Publisher: American Society of Hematology
Published: 2019-03-07
Volume: 133
Issue: 10
Pages: 1039-1048
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood-2018-10-844654
PMC: PMC7022316
OpenAlex: W2913296480
Cited by: 273
References: 81
Citations by year: 2026: 26 · 2025: 27 · 2024: 39 · 2023: 47 · 2022: 38 · 2021: 59 · 2020: 23 · 2019: 14
FWCI: 2.96
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Blood (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (P30CA076292)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Health Sciences › Medicine › Hematology › Blood disorders and treatments
Keywords: myelodysplastic syndrome, NLRP3 inflammasome, S100A9, pyroptosis, bone marrow microenvironment, myeloid-derived suppressor cells, innate immune activation, clonal hematopoiesis, cardiovascular morbidity, caspase-1, reactive oxygen species, Wnt/β-catenin signaling, disease biomarkers, disease-modifying therapy
MeSH terms: Pyroptosis, NLR Family, Pyrin Domain-Containing 3 Protein, Bone Marrow, Bone Marrow Cells, Hematopoiesis, Humans, Immunity, Innate, Inflammation, Mutation, Myelodysplastic Syndromes, Phenotype, Signal Transduction, Reactive Oxygen Species, Inflammasomes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks